Imfinzi approved in the EU for less-frequent, fixed- dose use in unresectable non-small cell lung cancer
15 January 2021 07:00 GMT Imfinzi approved in the EU for less-frequent, fixed-dose use in unresectable non-small cell lung cancer New option extends dosing from two to four weeks,reducing medical visits and improving patient convenience AstraZeneca's Imfinzi (durvalumab) has been approved in the European Union and the UK for an additional dosing option, a 1,500mg fixed dose every four weeks, in locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 on at least 1% of tumour cells and whose disease has not progressed following